CBS 2019
CBSMD教育中心
中 文

推荐文献

Abstract

Recommended Article

Post-Stroke Cardiovascular Complications and Neurogenic Cardiac Injury: JACC State-of-the-Art Review COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up Impact of Optimal Medical Therapy on 10-Year Mortality After Coronary Revascularization Association of Coronary Anatomical Complexity With Clinical Outcomes After Percutaneous or Surgical Revascularization in the Veterans Affairs Clinical Assessment Reporting and Tracking Program Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus Basic Biology of Oxidative Stress and the Cardiovascular System: Part 1 of a 3-Part Series Individualizing Revascularization Strategy for Diabetic Patients With Multivessel Coronary Disease

Original Research2018 Jun;25(3):769-776.

JOURNAL:J Nucl Cardiol. Article Link

Guidelines in review: Comparison of the 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes and the 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

Prejean SP, Din M, Reyes E et al. Keywords: Non-ST elevation acute coronary syndrome; coronary artery disease; non-invasive imaging; stress testing

ABSTRACT


In this Guidelines in Review, we review side-by-side the recommendations provided by the 2014 AHA/ACC Guideline for the management of patients with non-ST-elevation acute coronary syndromes and the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. We review the recommendations for imaging in the evaluation of patients with possible ACS followed by the diagnostic evaluation of patients with proven NSTE-ACS, based on their risk for adverse clinical events.